Qurient Co. Ltd Total Assets
Qurient Co. Ltd total assets. Based on the latest financial reports, Qurient Co. Ltd (115180) holds total assets worth ₩45.56 Billion KRW (≈ $30.88 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Qurient Co. Ltd (115180) total market value for the company's overall valuation and market capitalisation.
Total Assets of Qurient Co. Ltd (2014–2025)
Total assets of Qurient Co. Ltd from 2014 to 2025. This chart illustrates how Qurient Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Qurient Co. Ltd stock quote for real-time trading data and today's change.
Qurient Co. Ltd - Asset Composition Analysis
Qurient Co. Ltd Total Assets Breakdown (December 2025)
Qurient Co. Ltd total assets breakdown as of December 2025. Qurient Co. Ltd's total assets of ₩45.56 Billion consist of 83.2% current assets and 16.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 33.9% |
| Accounts Receivable | ₩536.84 Million | 0.9% |
| Inventory | ₩46.26 Million | 0.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.72 Billion | 7.6% |
| Goodwill | ₩666.75 Million | 1.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Qurient Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Qurient Co. Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qurient Co. Ltd's current assets represent 83.2% of total assets in 2025, a decrease from 95.3% in 2014.
- Cash Position: Cash and equivalents constituted 33.9% of total assets in 2025, down from 94.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 7.6% of total assets.
Qurient Co. Ltd Competitors by Total Assets
Key competitors of Qurient Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Qurient Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.35 | 12.66 | 11.37 |
| Quick Ratio | 10.34 | 12.64 | 11.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩32.03 Billion | ₩41.53 Billion | ₩38.64 Billion |
Qurient Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Qurient Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 50.39 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.5% |
| Total Assets | ₩61.99 Billion |
| Market Capitalization | $400.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Qurient Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Qurient Co. Ltd's assets decreased by 5.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Qurient Co. Ltd (2014–2025)
The table below shows the annual total assets of Qurient Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩61.99 Billion ≈ $42.01 Million |
-5.46% |
| 2024-12-31 | ₩65.57 Billion ≈ $44.44 Million |
+24.89% |
| 2023-12-31 | ₩52.50 Billion ≈ $35.58 Million |
+36.69% |
| 2022-12-31 | ₩38.41 Billion ≈ $26.03 Million |
-33.34% |
| 2021-12-31 | ₩57.62 Billion ≈ $39.05 Million |
-5.24% |
| 2020-12-31 | ₩60.81 Billion ≈ $41.21 Million |
+196.44% |
| 2019-12-31 | ₩20.51 Billion ≈ $13.90 Million |
-52.51% |
| 2018-12-31 | ₩43.20 Billion ≈ $29.27 Million |
+175.52% |
| 2017-12-31 | ₩15.68 Billion ≈ $10.62 Million |
-40.25% |
| 2016-12-31 | ₩26.24 Billion ≈ $17.78 Million |
+580.17% |
| 2015-12-31 | ₩3.86 Billion ≈ $2.61 Million |
-66.25% |
| 2014-12-31 | ₩11.43 Billion ≈ $7.75 Million |
-- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more